• Mintz, Levin, Cohn, Ferris, Glovsky and Popeo (New York) — a 480-lawyer AmLaw 100 firm with offices throughout the U.S. and the UK — has expanded its New York Health Law Practice with the addition of three attorneys. Andrew Roth, former head of McDermott, Will & Emery’s New York Health Law Practice, and David Ivill, also a former partner at McDermott, Will & Emery, have joined Mintz Levin’s Health Law Section as Members. Nili Yolin has joined as an associate.

W. Paul Constantine has resigned from his position as senior VP, sales at Misonix (Farmingdale, New York), effective Jan. 15 to take a position with the venture capital firm of Kleiner, Perkins, Caufield & Byers. Constantine will provide transitional support as existing in-house sales and marketing groups assume his responsibilities. Misonix makes ultrasonic medical device technology for the treatment of cancer and other chronic conditions.

Howard Robin has been named president/CEO for Nektar Therapeutics (San Carlos, California), effective Jan. 15. Robin will replace acting president/CEO Robert Chess who will remain company chairman. Robin formerly served as president/CEO of Sirna Therapeutics. Nektar makes drug delivery technologies.

Robert Feeney has been appointed VP, sales and marketing at NeoGenomics (Fort Myers, Florida). Feeney recently served in a dual capacity as the director of marketing and the director of scientific and clinical affairs for US Labs, a division of Laboratory Corporation of America. NeoGenomics is a CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing.

Suzanne Greenwood was named VP, sales, at OTN (South San Francisco), a physician services company and a distributor of products and services to the community physician market. Greenwood joins OTN as a member of the senior management team. Greenwood most recently was interim director of immunoscience medical science at BMS.